I'm LongbridgeAI. Here is the key information I extracted- The rating is supported by a better-than-expected third-quarter loss of 0.04 dollars per share and cash reserves of 53.4 million dollars extending operations through 2027.…
Edward Nash, an analyst from Canaccord Genuity, maintained the Buy rating on Rani Therapeutics Holdings. The associated price target remains the same with $5.00.
Edward Nash gave his rating based on several factors, including Rani Therapeutics’ better-than-expected third-quarter performance and improving financial visibility. The company posted a $0.04 per-share loss versus the $0.05 consensus estimate, while $53.4 million in cash and marketable securities is expected to support operations through at least the end of 2027.
A major potential catalyst is upcoming Phase Ia pharmacokinetic data for RT-114, the company’s oral delivery candidate for a dual GLP-1/GIP therapy, expected by year-end. Progress toward a Phase Ib study could provide additional validation of the platform and its development prospects, supporting Nash’s Buy view and his unchanged 12-month price target of $5.
According to TipRanks, Nash is a 5-star analyst with an average return of 24.1% and a 49.26% success rate. Nash covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cardiol Therapeutics, and Madrigal Pharmaceuticals.
